Article

Preparing to Exercise

What to know before beginning an exercise program

Everyone can do some type of activity. But it’s important that patients keep in mind a few general precautions before exercising during cancer treatment.

Patients who were already active may have to slow down a bit during treatment and perhaps not exercise as intensely as they had before. They should assess how they feel and avoid pushing themselves. It’s important for patients to communicate with their healthcare providers about their planned physical activities before they begin.

People who were sedentary before should start slowly, adding more intensity and frequency as they are able. Patients should consider how active they were before treatment and adjust accordingly.

Side effects of treatment can determine the most appropriate type of exercise. For example, someone with neuropathy may have numb toes, which would make riding a stationary bike a better choice than walking on a treadmill. Patients experiencing lymphedema have long been discouraged from upper body strength training or vigorous activity, but a number of clinical trials have shown that not only are these activities safe for these individuals, but also may actually reduce the incidence and severity of lymphedema. Patients must talk to their doctors to determine what is safe.

Patients who are undergoing frequent chemotherapy treatments may have lower immune function and should avoid working out in public places, such as gyms. People who are having skin reactions from radiation treatments and those with open wounds or catheters should avoid swimming in chlorinated pools.

An upper-body port may necessitate temporarily avoiding upper-body strength training. Patients with advanced disease who experience limitations due to bone metastases should discuss exercise with their healthcare provider and generally use pain or discomfort as a guide for what type of activity to avoid.

[Staying Active During Treatment]

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content